STRATA Skin Sciences to Participate in the MicroCap Rodeo Best Ideas Bowl

HORSHAM, PA / ACCESSWIRE / October 6, 2020 / STRATA Skin Sciences (NASDAQ:SSKN) (“STRATA”) a medical technology company in Dermatology and Plastic Surgery dedicated to developing, commercializing, and marketing innovative products for the treatment of dermatologic conditions, today announced that Dr. Dolev Rafaeli, STRATA’s Chief Executive Officer, will present a corporate overview at the MicroCap Rodeo Best Ideas Bowl, which is being held virtually on October 13th – 16th, 2020.

STRATA Skin Sciences, Inc. is scheduled to present on Tuesday, October 13th at 2:00 pm Eastern Time, with one-on-one meetings to be held throughout the conference. The presentation will be webcast live and available for replay at: www.strataskinsciences.com.

To receive additional information, request an invitation or to schedule a one-on-one meeting, please email mgensel@strataskin.com.

About the MicroCap Rodeo Best Ideas Bowl
The MicroCap Rodeo is back with its first ever “Best Ideas Bowl.” This conference is a virtual conference that brings you the top 25 best ideas from the buy side. Qualified institutional investors recommended each of the 25 companies represented as one of their best ideas. Those of you who attended the 2019 MicroCap Rodeo in Austin, Texas, know that we’re focused on alpha. The Best Ideas Bowl is sure to have some big winners too.

About STRATA Skin Sciences, Inc.

STRATA Skin Sciences is a medical technology company in Dermatology and Plastic Surgery dedicated to developing, commercializing and marketing innovative products for the treatment of dermatologic conditions. Its products include the XTRAC® excimer laser and VTRAC® lamp systems utilized in the treatment of psoriasis, vitiligo and various other skin conditions; and the STRATAPEN® MicroSystem, marketed specifically for the intended use of micropigmentation.

The Company’s proprietary XTRAC® excimer laser delivers a highly targeted therapeutic beam of UVB light to treat psoriasis, vitiligo, eczema, atopic dermatitis and leukoderma, diseases, which impact over 35 million patients in the United States alone. The technology is covered by multiple patents, including exclusive rights for patents for the delivery of treatments to vitiligo patients.

STRATA’s unique business model leverages targeted Direct to Consumer (DTC) advertising to generate awareness and utilizes its in-house call center and insurance advocacy teams to increase volume for the Company’s partner dermatology clinics.

The XTRAC® business has used this proven DTC model to grow its domestic dermatology partner network to over 789 clinics, with a worldwide installed base of over 2,000 devices. The Company is able to offer 90% of DTC patients an introduction to physicians prescribing a reimbursable solution, using XTRAC®, within a 10 mile radius of their house. The Company is a leader in dermatology in-clinic business generation for its partners.

Investor Contacts:

Matthew Hill, Chief Financial Officer
STRATA Skin Sciences, Inc.
215-619-3200
ir@strataskin.com

SOURCE: STRATA Skin Sciences

View source version on accesswire.com:
https://www.accesswire.com/609150/STRATA-Skin-Sciences-to-Participate-in-the-MicroCap-Rodeo-Best-Ideas-Bowl

Staff

Recent Posts

Self Regional Healthcare Brings Future-Ready Enterprise Imaging Cloud Technology Into South Carolina With AGFA Healthcare

Self Regional Healthcare aims to upgrade its PACS, enhance diagnostic imaging capabilities, and strengthen its…

27 minutes ago

Columbus, GA, Podiatrist Partners With Workforce Program to Offer Internship for Aspiring Healthcare Professionals

Ankle & Foot Centers of America's Columbus office, led by Dr. Jennifer Monaco, partners with…

27 minutes ago

Interactive Strength Inc. (Nasdaq:TRNR) Successfully Concludes Hearings Panel Appeal and Confirms Demonstrated Compliance Letter for Continued Nasdaq Listing

AUSTIN, TX / ACCESSWIRE / November 27, 2024 / Interactive Strength Inc. (NASDAQ:TRNR) ("TRNR" or…

27 minutes ago

Zomedica to Present at the NobleCon20 Twentieth Annual Emerging Growth Equity Conference December 4, 2024

ANN ARBOR, MI / ACCESSWIRE / November 27, 2024 / Zomedica Corp. (NYSE American:ZOM) ("Zomedica"…

27 minutes ago

SELLAS Announces Positive Data from Preclinical Studies Indicating ASXL1 Mutations as Predictor of Response to SLS009 in Solid Cancers

- Preselection Method for Cancers Responding to SLS009: High Efficacy of SLS009 Observed in 67%…

28 minutes ago

PHAXIAM Therapeutics presents an ambitious development strategy to take advantage of the rapidly evolving Phages therapy area

Webinar being held today "Evolving strategic context for phages, Introducing new opportunities" to present PHAXIAM…

28 minutes ago